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Abstract  
Objectives: Several randomised controlled trials (RCTs) on the use of probiotics to reduce 
morbidity and mortality in preterm infants have provided inconsistent results. Whilst meta-
analyses that group all of the used strains together, suggest efficacy, it is not possible to 
determine the most effective strain which is more relevant to the clinician. We therefore used a 
network meta-analysis (NMA) approach in order to identify strains with greatest efficacy. 
Methods: A PubMed search identified placebo-controlled or head-to-head RCTs investigating 
probiotics in preterm infants. From trials that recorded mortality, necrotising enterocolitis (NEC), 
late-onset sepsis (LOS), or time until full enteral feeding (TUFEF) as outcomes, data were 
extracted and Bayesian hierarchical random effects models were run to construct a NMA.  
Results: Fifty-one RCTs involving 11,231 preterm infants were included. Most strains or 
combinations of strains were only studied in one or a few RCTs. Only 3 out of 25 studied 
probiotic treatment combinations showed significant reduction in mortality rates. Seven 
treatments reduced NEC incidence, 2 reduced LOS, and 3 reduced TUFEF. There was no clear 
overlap of strains which were effective on multiple outcome domains.  
Conclusions: This NMA showed efficacy in reducing mortality and morbidity only in a minority 
of the studied strains or combinations. This may be due to an inadequate number, or size, of 
RCTs, or due to a true lack of effect for certain species. Further large and adequately powered 
RCTs using strains with the greatest apparent efficacy will be needed in order to more precisely 
define optimal treatment strategies. 
 
Keywords: Premature neonates; necrotising enterocolitis; sepsis; enteral tolerance; microbiota 
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What is known: 
‐ Several RCTs show that probiotics reduce neonatal morbidity and mortality, but data are 
inconsistent. 
‐ Multiple different probiotic strains or combinations have been used in these RCTs. 
‐ Most existing meta-analyses group different strains and fail to adequately account for 
strain specific effects. 
What is new: 
‐ Network meta-analysis shows that only a minority of probiotic strains have a statistically 
significant effect in reducing mortality and morbidity in preterm infants. 
‐ The absence of significant effects may reflect a lack of adequately powered RCTs, or a 
genuine lack of efficacy for those species or strains.  
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Introduction 
Necrotising enterocolitis (NEC) is a devastating disease in preterm infants strongly associated 
with gestational age, that has a variable incidence but typically averages 5-10% in infants 
weighing <1500 g (1). Mortality rates vary but range from 10 to 30%. Its pathogenesis is not 
completely understood as its occurrence may be the result of a variety of different aetiologies (2-
4), and early detection is difficult (5-7). Accumulating evidence shows that in addition to the 
effect of human milk feeding (8-10), probiotics may be important (11) in preventing NEC and 
reducing mortality (12, 13).The role of the gut microbiota in the pathogenesis of NEC is, 
however, still unclear (14-16). Caution has therefore been advised until appropriately regulated 
safe products are available for use in this high-risk population (12, 16, 17). In its commentary 
published in 2010 on enteral nutrition in preterm infants the European Society for Paediatric 
Gastroenterology, Hepatology and Nutrition (ESPGHAN) Committee on Nutrition did not 
recommend routine probiotics administration in infants less than 1800 g (18). 
Numerous meta-analyses have recently been published summarizing a large number of 
randomised clinical trials (RCTs) (19-32). In almost all of these meta-analyses the experimental 
group was constructed after pooling a wide variety of different probiotic strains as used in the 
original trials. This approach, however, does not give the clinician a meaningful answer as to 
which specific probiotic product has evidence-based efficacy. To partly overcome this problem, 
genus specific meta-analyses have been performed as well (25, 31). However, also within genera 
or species there might be significant differences in effectiveness depending on precise strain. 
Therefore, efficacy can only be evaluated at strain level and such meta-analyses have previously 
only been performed twice (21, 22). 
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Classical pair-wise meta-analyses address the comparative effectiveness among similar or 
competing interventions against a common comparator (usually placebo or standard care). In 
addition, these omit direct evidence from the few studies that provide head-to-head comparisons 
on probiotic strains. Network meta-analyses (NMA), however, can address multiple 
interventions simultaneously. This method allows a system to visualize and statistically combine 
evidence from direct comparisons with evidence from indirect comparisons across several 
competing interventions. By employing a NMA on data from RCTs of probiotics in preterm 
infants, our objective was to develop an updated and clinically meaningful understanding of the 
relative effectiveness of the different probiotic treatments.  
 
Methods 
Protocol registration and reporting guidelines 
This systematic review was registered on PROSPERO (international prospective registry of 
systematic reviews) under number CRD42017064847. This manuscript is conducted and 
reported according to the methods and recommendations of the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) Extension Statement for Reporting of 
Systematic Reviews incorporating NMA (33).  
Eligibility criteria 
Inclusion criteria were studies that included only preterm infants, or studies that reported sub-
groups between term and preterm infants so that only results from the latter could be included. 
Preterm birth was defined as gestational age of less than 37 weeks. Studies comparing probiotic 
treatment against placebo, usual care, or head-to-head with a different probiotic regime were 
considered eligible. If a study intervention consisted of the combination of a probiotic strain 
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together with another form of intervention, such as prebiotics or lactoferrin, the study was only 
included if a control group was included which received the same non-probiotic intervention 
(e.g. prebiotics or lactoferrin), but without the probiotic intervention. Studies could be included 
when infants were fed own mother’s milk, donor milk or formula. Single or multiple strain 
studies were included. Studies were included if they reported well-described outcome reports of 
NEC (with Bell stages included (34-36)), blood-culture proven late-onset sepsis (LOS), postnatal 
age at reaching full enteral feeding (150 mL/kg per day), or in-hospital mortality. Other 
outcomes were not considered in this report. We included only RCTs (including cluster RCTs) 
which were fully published and in the English language. Complete blinding was not considered 
as mandatory. The results from non-randomised studies, conference papers, abstracts, or other 
non-published studies were not included.  
Search strategy 
A systematic literature search was conducted using the PubMed database from inception to 
September 19th, 2017. Search terms were: probiotic* AND (premature OR preterm OR neonat* 
OR infant*), with a limit on ‘Clinical Trial’. In addition, reference lists of previously published 
meta-analyses were screened to identify additional eligible studies. The literature search was 
conducted independently by two reviewers (CHvdA and JBvG).Inconsistency whether to include 
a study was resolved by discussion.  
Data extraction  
Two round table meetings of the group (May 2016, Athens and May 2017, Prague) were held to 
achieve consensus on the approach, outcomes assessed, methods and to resolve all differences in 
interpretation of the methodological assessment and results of the eligible trials.  
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From the eligible studies information regarding inclusion criteria, study groups, key 
characteristics, and outcomes was extracted by the two reviewers independently using a 
standardized data collection form. Missing data were requested by contacting the authors. 
Probiotic strains were identified at strain levels (e.g. Lactobacillusrhamnosus GG ATCC 53103 
or Bifidobacteriumanimalis subspecies lactis Bb-12), although often this was not available in the 
original reports. If no email reply was received from the original authors, strain numbers were 
obtained if possible through contacting manufacturers or internet searches on available product 
names.  
For the remainder of this manuscript probiotic strains are truncated at their genus: Bacillus, 
Bifidobacterium, Enterococcus, Lactobacillus, Saccharomyces, and Streptococcus are denoted 
by Ba., B., E., L.,Sa., and S., respectively. In addition, subspecies (subsp) names are truncated as 
well: B.animalis subsp lactis is denoted as B.lactis; B.bifidum subsp infantis as B.infantis; 
B.bifidum subsp longum as B.longum, and S. salivarius subsp thermophilus as S. thermophilus. 
Over past decades multiple reclassifications in taxonomy have been proposed and designations in 
the historical publications may no longer be accurate. We therefore adhered to the latest 
nomenclature we were aware of. For example, B.infantis 35624 is designated as B.longum 35624 
(37), B.bifidum Bb-12 as B.lactis Bb-12 (38), and L.sporogenes as Ba.coagulans(39). Since the 
L.reuteri strain DSM 17938 is a daughter strain of L.reuteri ATCC 55730 in which only 
resistance plasmids were removed but other characteristics are maintained (40), these strains are 
analysed together. Similarly, as B.lactis B94 shares many characteristics with B.lactis Bb-12 
(41), these strains are also analysed together in our NMA. Except for in our study summary table 
1, all control groups will be further denoted as placebo, whether true placebo was used, or 
whether usual care was given.  
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In case continuous data (i.e. data on time until full enteral feeding (TUFEF)) were originally 
presented as medians with corresponding interquartile percentiles or outer ranges, data were 
converted to estimated means with standard deviations, as previously described (42, 43). 
Obtained data were compared to previously published systematic reviews and discrepancies were 
rechecked in the original trials. 
Assessment of study quality 
To assess the methodological quality of the included RCTs the Cochrane Collaboration’s tool for 
assessing risk of bias was used. The tool includes the following criteria: adequacy of sequence 
generation, allocation concealment, blinding of participants, personnel and outcome assessors, 
incomplete outcome data, selective reporting, and other biases (43). Noteworthy, studies were 
not excluded based on these results. Items were scored as low, high, or unknown risk of bias. 
Because of possible probiotic cross colonization from intervention to control groups, the item on 
other biases was scored as unknown, except in case of cluster RCTs. Publication bias was 
assessed by constructing funnel plots for each outcome.  
Statistical analyses  
Studies were compared between every studied probiotic strain or combination of studied strains 
via a comprehensive NMA based on the Bayesian theorem (44, 45). This approach can be 
considered to be an extension of the traditional pair-wise meta-analysis, as it incorporates both 
direct and indirect information through a common comparator (most often placebo or routine 
care) to obtain estimates of the relative interventional effects on multiple intervention 
comparisons.  
Network graphs were constructed for each outcome variable. They consisted of nodes (points 
representing the competing interventions) and edges (adjoining lines between the nodes that 
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show which interventions have been compared among the included studies). The size of the 
nodes represent the number of infants that received the intervention. The thickness of the edges 
represent the number of comparative studies between the respective nodes. Reviewing the 
network geometry graphically summarizes how the evidence base is built up and whether various 
strains were directly compared or only through indirect network evidence. 
We made use of the Aggregate Data Drug Information System 2 (ADDIS2) software (46, 47), 
which is an open-source online application based on R statistical software (48). The NMA was 
conducted using a Bayesian framework in combination with a Markov chain Monte-Carlo 
simulation. Given that most treatments included a limited number of RCTs, we assumed 
between-study heterogeneity, although this could not formally be tested. Therefore, a 
conservative random effect approach was employed in our NMA models.The NMA was run with 
an outcome scale of 5 to set default prior distributions accordingly. Run-lengths were based on at 
least 80000 inference iterations for each 4 chains with a burn-in period of the first 10000 
iterations combined with a thinning factor of 10. Convergence was assessed using the Brooks-
Gelman-Rubin diagnostic to reassure that all potential scale reduction factors (PSRFs) remained 
below 1.05. In the rare occasion that the PSRF approached 1.05 or was higher than 1.05, run-
length was increased accordingly to improve model convergence. 
Relative treatment effect plots were constructed for each studied probiotic strain (or combination 
of multiple strains) versus placebo. Dichotomous outcomes are expressed as risk ratios (RRs) 
with their 95% credible interval (95% CrI). Continuous outcome measures are expressed as mean 
differences with their 95% CrI. 
Besides the relative effect plots in the NMA, we constructed classic pair-wise forest plots for 
those strains or combinations which were compared to placebo if they showed either significant 
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efficacy in the NMA or were evaluated in at least two RCTs and at least 250 infants were 
included in the treatment arm. These forest plots were constructed in RevMan (49) and visualise 
how the NMA evidence base is built up.  
Consistency of the NMA model between direct and indirect network evidence was tested with 
the node splitting method (50). A known drawback from this approach, however, is that it cannot 
properly handle multi-arm studies (44). To give insight in possible publication biases, we 
constructed funnel plots for all studies that compared placebo versus any probiotic strain or 
combination for each outcome separately. 
 
Results 
Our PubMed search yielded 515 citations; a flow diagram on the screening and eligibility 
process is presented in figure 1. In total 56 articles (for 49 different RCTs) were identified which 
fulfilled our inclusion criteria and reported usable extractable outcome data on at least one of our 
predefined outcome domains (51-106). Five of these articles only showed overlapping data and 
were further discarded (102-106). Two studies were either a sub-study (65) from a multicentre 
study (51), or an extension (75) of an already published trial (74); from the sub-studies only data 
not elsewhere reported was entered in our database. One small RCT only described that NEC, 
sepsis, and mortality incidence were not different between groups (107), but no response was 
received from the authors after requesting original data. Eight studies were identified with 
appropriate study design and inclusion criteria, although no data on our outcome domains were 
described (108-113) or only long-term follow-up data was presented (114, 115). In 4 studies, the 
use of probiotics was not the only difference between intervention and control groups, i.e. 
prebiotics were used only in the intervention group (116, 117), or only the control group received 
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nystatin instead of placebo (118, 119). One study included both preterm and term neonates and 
results were not split between subgroups (120). The studies from which no suitable data on our 
outcome domains could be extracted, were therefore excluded from further analysis in this report 
(107-120). From the 51 included articles (51-101), data from 11,231 preterm infants could 
potentially be extracted. Table 1 shows study details and main characteristics of the included 
patients. Based on broadly overlapping basic inclusion criteria and patient characteristics across 
the various trials we assumed transitivity (33, 44). Identified strain numbers are summarized in 
appendix table S1 (Supplemental Digital Content, http://links.lww.com/MPG/B273). 
Unfortunately, we were not able to retrieve them for all microorganisms. Results for which no 
strain number is available must therefore be interpreted with caution as different products might 
have been used. Appendix figures S1A&B (Supplemental Digital Content, 
http://links.lww.com/MPG/B273) show the risk of bias assessment.  
Mortality 
Figure 2 shows the network graph comparing the probiotic strains or combinations as used in the 
original trials for the reduction of in-hospital mortality. The network geometry shows the 
evidence base comparing 25 different treatments (n=4788 in total in 39 arms; mortality incidence 
5.1%) versus the common comparator placebo (n=4512 in 36 trials; mortality incidence 7.0%). 
Original mortality incidence data from all included studies is shown in appendix table S2 
(Supplemental Digital Content, http://links.lww.com/MPG/B273). There were only 4 direct 
head-to-head comparisons. Three interventions had to be excluded from the quantitative analysis 
because there were zero events in the placebo or intervention groups which is not compatible 
with NMA analyses. In one study using Sa.boulardii CNCM I-3799 (100), there were no 
mortality cases in both the intervention and control groups; Three studies (2 treatments: 
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B.bifidum OLB6378 (95); and B. breve M-16V (67, 81)) were excluded because there were zero 
events in the intervention groups, although mortality rates in the placebo groups from these 
studies amounted 2/153 and 4/176, respectively (events/N).  
Figure 3 shows the relative effects plot for efficacy in reducing mortality of the various tested 
probiotic strains or tested combinations versus placebo treatment. It shows that the RRs for 
mortality are significantly reduced for 3 interventions: for the combination of B.bifidum NCDO 
1453 and L.acidophilus NCDO 1748 (based on 2 studies with 494 infants (72, 87)); the 
combination of B.bifidum, B.infantis, B.longum, and L.acidophilus (based on 1 study with 186 
infants (88)); and the combination of B.infantis, L.acidophilus, L.casei, L.plantarum, 
L.rhamnosus, and S.thermophilus altogether (based on 1 study with 150 infants (63)); see also 
table 2. Separate pair-wise forest plots are shown in appendix figure S2 (Supplemental Digital 
Content, http://links.lww.com/MPG/B273) for probiotic strains or combinations which were 
significant or were tested in at least 250 infants versus placebo. Node-splitting detection of 
inconsistency was not possible in this model due to only head-to-head trials from multiple arm 
studies, or head-to-head comparisons with 0 events in one or more study arms (50). A funnel plot 
shows no clear evidence of a publication bias (appendix figure S3, Supplemental Digital 
Content, http://links.lww.com/MPG/B273). 
Necrotising enterocolitis 
Figure 4 shows the network graph comparing the probiotic strains or combinations as they were 
used in the original trials for the prevention of NEC grades 2 or 3. The network geometry shows 
the evidence base comparing 25 different treatments (n=5550 in total in 50 arms; NEC incidence 
3.2%) versus the common comparator placebo (n=5101 in 43 trials; NEC incidence 6.1%). 
Original NEC incidence data from all included studies is shown in appendix table S3 
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(Supplemental Digital Content, http://links.lww.com/MPG/B273). There were only 6 direct 
head-to-head comparisons. Three studies (using Ba.clausii 4 strains (94); B.bifidum OLB6378 
(95); and Sa.boulardii CNCM I-3799 (100)) had to be excluded from the NMA because there 
were zero events in both the placebo and intervention groups. Seven studies (4 treatments: 
B.breve M-16V (64, 67, 81, 98); B.breve and L.casei(55); B.infantis PTA-5843, E. faecium PTA-
5844, and L.gasseri PTA-5845 (70); and L.acidophilus Lb (53)) were excluded because there 
were zero events in the intervention groups, although NEC rates in the placebo groups from these 
studies amounted 1/127, 4/112, 5/40, and 5/16, respectively (events/N).  
Figure 5 shows the relative effects plot for efficacy in reducing NEC grade 2 or 3 of the various 
tested probiotic strains or tested combinations versus placebo treatment. It shows that the RRs 
for NEC are significantly reduced for 7 treatments: B.lactis Bb-12 or B94 (based on 5 trials with 
828 infants (61, 66, 76, 78, 93)); L.reuteri ATCC 55730 or DSM 17938 (based on 4 studies with 
1459 infants (79, 83, 84, 91)); L.rhamnosus GG (based on 6 studies with 1507 infants (56, 59, 
73, 75, 84, 96)); the combination of B.bifidum, B.infantis, B. longum, and L.acidophilus (based 
on 2 studies with 247 infants (88, 96)); the combination of B.infantis ATCC 15697 and 
L.acidophilus ATCC 4356 (based on one study with 367 infants (71)); the combination of 
B.infantis Bb-02, B.lactis Bb-12, and S.thermophilus TH-4 (based on 2 studies with 1244 infants 
(54, 69)); and the combination of B.longum 35624 and L.rhamnosus GG (based on 2 studies with 
285 infants (51, 97)); see also table 2. Separate pair-wise forest plots are shown in appendix 
figure S4 (Supplemental Digital Content, http://links.lww.com/MPG/B273) for probiotic strains 
or combinations which were significant or were tested in at least 250 infants versus placebo. 
Node-splitting models did not show substantial differences between direct and indirect evidence, 
so that the consistency model holds (appendix figure S5, Supplemental Digital Content, 
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http://links.lww.com/MPG/B273) (50). The funnel plot shows no clear evidence of a publication 
bias (appendix figure S6, Supplemental Digital Content, http://links.lww.com/MPG/B273). 
Late-Onset Sepsis 
Figure 6 shows the network graph comparing the probiotic strains or combinations as they were 
used in the original trials for the prevention of culture proven LOS. The network geometry shows 
the evidence base comparing 25 different treatments (n=5576 in total in 52 arms; sepsis 
incidence 15.4%) versus the common comparator placebo (n=5049 in 45 trials; sepsis incidence 
24.9%). Original LOS incidence data from all included studies is shown in appendix table S4 
(Supplemental Digital Content, http://links.lww.com/MPG/B273). There were only 6 direct 
head-to-head comparisons. One intervention using Sa.boulardii CNCM I-3799 had to be 
excluded because there were zero events in both the placebo and intervention groups (100).  
Figure 7 shows the relative effects plot for efficacy in reducing LOS of the various tested 
probiotic strains or tested combinations versus placebo. It shows that the RRs for LOS are 
significantly reduced for 2 probiotic treatments: for the combination of B.bifidum, B.infantis, B. 
longum, and L.acidophilus (based on 2 studies with 247 infants (88, 96)); and for the 
combination of B. longum R00175, L. helveticus R0052, L. rhamnosus R0011, and Sa. boulardii 
CNCM I-1079(based on 3 studies with 241 infants (52, 62, 92)); see also table 2. Separate pair-
wise forest plots are shown in appendix figure S7 (Supplemental Digital Content, 
http://links.lww.com/MPG/B273) for probiotic strains or combinations which were significant or 
tested in at least 250 infants versus placebo. Node-splitting models did not show substantial 
differences between direct and indirect evidence, so that the consistency model holds (appendix 
figure S8, Supplemental Digital Content, http://links.lww.com/MPG/B273) (50). The funnel plot 
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shows no clear evidence of a publication bias (appendix figure S9, Supplemental Digital 
Content, http://links.lww.com/MPG/B273). 
Time until full enteral feeding 
Figure 8 shows the network graph comparing the probiotic strains or combinations as they were 
used in the original trials to reduce TUFEF. The network geometry shows the evidence base 
comparing 13 different treatments (n= 3122 in 24 arms) versus the common comparator placebo 
(n=2988 in 21 trials). There were only 2 direct head-to-head comparisons. Original data from all 
included studies is shown in appendix table A5 (Supplemental Digital Content, 
http://links.lww.com/MPG/B273). Figure 9 shows a relative effects plot for efficacy in reducing 
TUFEF of the various tested probiotic strains or tested combinations versus placebo treatment. It 
shows that the mean difference for TUFEF is significantly reduced for 3 interventions: L.reuteri 
ATCC 55730 or DSM 17938 (based on 3 studies with 626 infants (79, 84, 91)); and for the 
combination of B.bifidum, B.infantis, B. longum, and L.acidophilus (based on 2 studies with 247 
infants (88, 96)); and for the combination of B.longum BB536 and L.rhamnosus GG (based on 1 
study with 94 infants (85)); see also table 2. Separate pair-wise forest plots are shown in 
appendix figure S10 (Supplemental Digital Content, http://links.lww.com/MPG/B273) for 
probiotic strains or combinations which were significant or tested in at least 250 infants versus 
placebo. Node-splitting models did not show substantial differences between direct and indirect 
evidence, so that the consistency model holds (appendix figure S11, Supplemental Digital 
Content, http://links.lww.com/MPG/B273) (50). From the funnel plot, a publication bias could 
not be excluded, as no clear triangular shape could be identified from included studies (appendix 
figure S12, Supplemental Digital Content, http://links.lww.com/MPG/B273). 
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Discussion: 
By using the approach of a NMA, we were able to determine, based on the current literature, 
which tested probiotic strains were most effective, and which were not, in reducing mortality and 
morbidity in preterm infants. Only 3 out of 25 studied probiotic treatments showed significant 
reduction in mortality rates. Seven treatments reduced NEC incidence, 2 reduced LOS, and 3 
reduced TUFEF. There was no clear overlap of certain strains which were significantly effective 
on multiple outcome domains. Most strains or combination of strains only showed trends 
towards efficacy, whereas other strains did not demonstrate efficacy (such as Sa.boulardii 
CNCM I-745 andB.breve BBG-001). A lack of effect may either be due to understudied species 
or a true lack of effect of certain strains.  
Although the total number of 51 RCTs included with over 11,000 infants is considerable (51-
101), many  of the different probiotic treatments were only evaluated in one or two trials. Only 
five strains were studied in at least 4 RCTs (see also tables S2-5): B.breve M-16V, B.lactis Bb-
12 or B94, L.reuteri ATCC 55730 or DSM 17938, L.rhamnosus GG ATCC 53103, and 
Sa.boulardii CNCM I-745. In addition, the evidence base was frequently dependant on small, 
lower quality, or outdated studies as can be seen in the pair-wise forest plots. We chose to 
include moderately preterm infants in our analyses noting that the number of studies which 
focussed on the smallest infants was very limited. In only 4 of the 51 included studies 
(compromising 3 different RCTs), the mean birth weight was below 1000 g (table 1) (51, 65, 76, 
97). In 10 studies, the mean birth weight was at least 1500 g. There were many studies with 
unclear risks of bias for the various domains, and 8 studies with high risks in at least 1 domain 
(64, 67, 70, 82, 84, 87, 98, 101). However, most of the studies with a high risk of bias assessment 
did not contribute to the significant strains. An unclear risk indicates that the risk item was not 
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clearly described, but does not necessarily indicate a potentially flawed study. We decided not to 
exclude studies purely on the basis of the quality assessment criteria, but allow readers to make 
their own interpretation of the evidence base. A visual inspection of the evidence bases by means 
of the funnel plots did not show a clear publication bias for most outcomes, although for TUFEF 
no triangular shape could be identified.  
In most of the original studies the primary outcome was not on one of our outcome domains 
(table 1), but on for example stool colonization, growth rates, or not reported even more 
frequently. If one performs a power calculation (α 5%; 1-β 80%) on reducing mortality rates 
while taking the observed rates in our manuscript (7.0 vs 5.1%), one would need almost 2500 
infants for each studied strain. For NEC, to demonstrate a reduction from 6.1 to 3.2%, one would 
need more than 800 infants per group. These high inclusion rates have not been reached for these 
outcomes. One must therefore realise that the results here presented are based on exploratory 
data analysis and thus only have hypothesis generating power.  
It must be noted that some interesting results were produced. For example, both L.rhamnosus 
GG and B.lactis Bb-12 / B94 appeared to be effective in reducing NEC (figure 5 and figure S4). 
In addition, B.longum BB536 showed a clear trend towards a similar effect. However, both the 
combination of L.rhamnosus GG with B.longum BB536 and the combination of B.lactis Bb-12 
with B.longum BB536 showed no measurable effect. This may reflect an antagonistic effect of 
B.longum BB536 together with the other two strains, or the relatively poor evidence base on 
which this NMA is built. A similar pattern was seen with these strains in the reduction of LOS, 
although much less pronounced. Somewhat un-expectedly, only L.rhamnosus GG 
simultaneously administered with B.longum BB536 was able to reduce TUFEF significantly 
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(based on 1 study with 94 infants studied (85)), whereas L.rhamnosus GG alone was not (figure 
9 and figure S10). 
The classic strain versus placebo forest plots show that the effect size was more or less similar to 
evidence from relative effect plots in the NMA. The small differences can be explained due to 
the Bayesian statistical approach versus the classic frequentist random-effects models, but it is 
known that Bayesian techniques better account for trial heterogeneity. In addition, the NMA 
gained extra power from indirect network evidence, from studies in which there was no suitable 
placebo group but only provided head-to-head comparisons (96, 101), and from studies in which 
data from multiple treatment arms could be included (66, 84). Unfortunately, most network 
evidence was based on indirect comparisons as the vast majority only compared treatment versus 
placebo or routine care. There were only a few head-to-head trials available that could be tested 
for inconsistency by means of the node splitting method. Nevertheless, inconsistency between 
direct and indirect network evidence was not apparent in tested cases.  
As is the case for almost any meta-analysis, there are small differences in study design in terms 
of inclusion criteria (e.g. birth weight, gestational age, degree of growth restriction) or drug 
administration regimens (initiation, duration, and dosing). Although most studies did not exclude 
infants depending on their dietary exposures (formula, own mother’s milk, or donor milk), some 
studies only included infants who either received only breast milk, or only formula. The 
magnitude of how this affected results is unknown. Nevertheless, transitivity was assumed as 
inclusion criteria were all broadly overlapping. A further bias could be that we included only 
RCTs published in the English language due to language barriers for reviewing. On the other 
hand, most RCTs from other settings such as for example China used different combinations of 
strains that were not tested in the RCTs included here (29). A major strength of our analysis, is 
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that we paid meticulous attention to retrieve the correct probiotic strain in the included RCTs. 
Regrettably, strain numbers were frequently not mentioned in the original manuscripts and could 
sometimes not be retrieved despite contacting original authors or companies. The results from 
species without further designation should therefore be interpreted with caution. It is no longer 
acceptable in current studies to omit a clear description of the used probiotic drug at subspecies 
level with strain number according to the latest taxonomic nomenclature (17, 121). In addition, 
many commercial products turned out to contain different bacterial strains than were included on 
the ingredient list (17, 122). Future studies should therefore validate their studied probiotic 
strains and exclude contamination by other strains. Apart from efficacy, a high degree of quality 
control and assurance is mandatory as probiotic related sepsis has been regularly reported in 
preterm infants who can be considered immuno-compromised patients (17, 31). An additional 
safety issue could be that some probiotics strains carry antibiotic resistance genes themselves, 
and could thus have the potential to pass the antibiotic resistance genes to pathogenic bacteria 
through horizontal gene transfer (123). These elements need to be taken into account when 
balancing supposed or true beneficial and harmful effects.  
To conclude, our efforts in this study were to present an overview of all published evidence on 
the use of probiotics in preterm infants at a strain level, and to identify the most promising 
strains. Most strains were unfortunately only studied once or a few times. In addition, the number 
of reports in the most preterm neonates was very limited. Furthermore, it was not possible to 
determine optimal probiotic dosages, time of initiation, and duration of treatment course. 
Nevertheless, we believe that our approach of a strain-specific NMA gives a much more 
meaningful answer than previously performed meta-analyses in which all probiotic strains were 
analysed as one group, or were grouped at a genus or species level, as even these latter analyses 
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do not address strain specific characteristics. The NMA allowed us to identify potential strains 
that can reduce NEC and mortality incidence in this vulnerable population. Still, our major and 
rather disappointing conclusion, is that more than 10 years from the first RCTs showing that 
probiotics may reduce a disease as serious as NEC, we remain unable to clearly identify the 
optimal strain, dose or combination, and that clinicians are left using inadequately tested, 
potentially un-safe and possibly ineffective treatments.   
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Table 1: Overview of included studies with their design, who prepared the control and intervention drugs, main inclusion 
criteria, feeding modality, duration of intervention, used probiotic strains including dose and manufacturer if provided, included 
number of patients (N), average gestational age (GA) and birth weight (both reported as mean and SD unless specified otherwise 
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1.0 
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DB double blind; PC placebo controlled; CR cluster randomized; NR not reported; AGA appropriate for gestational age; DOL day of 
life; OMM own mother’s milk; DM donor milk; PF preterm formula; PMA post menstrual age; PCA post conceptual age; CFU colony 
forming units; CPU cells per unit; NEC necrotising enterocolitis; LOS late-onset sepsis; TUFEF time until full enteral feeding. 
* Personal communication with original authors; ** No reply from original authors upon inquiry of more details; NEC 2 or 3 was 
assumed in analyses 
§ Median; # Median (IQR); $ Median (range) 
1 In the original manuscript it is stated they used B. bifidum, which turned out to beB. bifidum Bb-12, nowadays better known as B. 
lactis Bb-12 
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Table 2: Summary of significantly effective strains or combinations in reducing mortality, NEC grade 2 or 3, late-onset sepsis, or time 






Risk ratio or mean difference (in 
days) with their 95% credible 
intervals 
 B. bifidum NCDO 1453 and L. 
acidophilus NCDO 1748 
2 494 0.16 (0.019 – 0.74) 
 B. bifidum, B. infantis, B. 
longum, and L. acidophilus 
1 186 0.26 (0.059 – 0.98) 
 B. infantis, L. acidophilus, L. 
casei, L. plantarum, L. rhamnosus, and 
S. thermophilus 
1 150 0.090 (0.0034 – 0.70) 
NEC grade 2 or 3 (RR):    
 B. lactis Bb-12 or B94 5 828 0.25 (0.10 – 0.56) 
 L. reuteri ATCC 55730 or DSM 
17938 
4 1459 0.43 (0.16 – 0.98) 
 L. rhamnosus GG 6 1507 0.24 (0.064 – 0.67) 
 B. bifidum, B. infantis, B. 
longum, and L. acidophilus 
2 247 0.25 (0.051 – 0.89) 
 B. infantis ATCC 15697 and L. 
acidophilus ATCC 4356 
1 367 0.16 (0.017 – 1.0) 
 B. infantis Bb-02, B. lactis Bb-
12, and S.thermophilus TH-4 
2 1244 0.29 (0.073 – 0.78) 
 B. longum 35624 and L. 
rhamnosus GG 
2 285 0.18 (0.020 – 0.89) 
Late-onset sepsis (RR):    
 B.bifidum, B.infantis, B. longum, 
and L.acidophilus 
2 247 0.43 (0.18 – 0.94) 
 B. longum R00175, L. helveticus 
R0052, L. rhamnosus R0011, and Sa. 
boulardii CNCM I-1079 
3 241 0.34 (0.16 – 0.66) 
Time until full enteral feeding (d):    
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 L.reuteri ATCC 55730 or DSM 
17938 
3 626 -3.3 (-6.4 – -0.62) 
 B.bifidum, B.infantis, B. longum, 
and L.acidophilus 
2 247 -4.7 (-8.6 – -0.70) 
 B.longum BB536 and 
L.rhamnosus GG 
1 94 -10 (-16 – -3.6) 
 
